- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has granted approval for tbo-filgrastim (XM02 filgrastim), ...

SCF has been shown to synergize with G-CSF to mobilize CD34 + PBPCs. In this study we report results from this combination after a phase II trial of 32 patients with malignant lymphoma randomized to ...

FDA approved Teva Pharmaceuticals’ short-acting recombinant G-CSF product tbo-filgrastim (XM02 filgrastim) for reducing the duration of severe neutropenia in patients with nonmyeloid cancers receiving ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/wgccg4/filgrastim_and) has announced the addition of the "Filgrastim ...

We decided to conduct an analysis of follow-up policy and haematological malignancy incidence in related sibling donors of allogeneic PBSC mobilised with G-CSF filgrastim in the period of 2001–2010 at ...

A study published in the Journal of Managed Care & Specialty Pharmacy found that filgrastim and filgrastim-sndz were noninferior for the prevention of febrile neutropenia events that would require ...

GRANIX (tbo-filgrastim) Injection Teva announced that the FDA has approved Tbo-filgrastim (XM02 filgrastim injection solution), the first granulocyte colony-stimulating factor (G-CSF) to be approved ...

With the increasing emergence of less expensive biologic alternatives, some health systems are making the switch. For a large healthcare system, the arrival of a cheaper alternative to filgrastim ...

From October 1991 to April 1994, 506 stage I and II breast cancer patients were randomly assigned to receive, in a factorial 2 × 2 design, epirubicin 120 mg/m 2 and cyclophosphamide 600 mg/m 2 ...

First New Treatment for Neutropenia Approved in the United States in 10 YearsMarks First Supportive Care Therapy for Cancer Patients from Teva Oncology JERUSALEM, Aug 30, 2012 -- Teva Pharmaceutical ...

From October 1991 to April 1994, 506 stage I and II breast cancer patients were randomly assigned to receive, in a factorial 2 × 2 design, epirubicin 120 mg/m 2 and cyclophosphamide 600 mg/m 2 ...